Charles Addington, DO
Family Medicine · Lubbock, TXNPI 1508837790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$805
- AstraZeneca$637
- AbbVie$626
- Amgen$619
- Lilly USA, LLC$572
- Mylan Specialty L.p.$481
- plus $2K from 32 others
Across 5 payments — averaging $32,039 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$160K
What the payments were for
- Food & beverage$5,884100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$140
How this compares
$5,886 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArexvyRsvpref3 Antigen/As01e/Pf | 4,203 | $1,245,124 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 3,445 | $722,431 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 350 | $105,917 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 1,085 | $70,058 |
| EliquisApixaban | 71 | $45,968 |
| FarxigaDapagliflozin Propanediol | 67 | $43,593 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $26,461 |
| OzempicSemaglutide | 24 | $25,049 |
| JardianceEmpagliflozin | 16 | $20,758 |
| MounjaroTirzepatide | 17 | $19,324 |
| JanuviaSitagliptin Phosphate | 34 | $18,759 |
| TwinrixHepatitis A And B Vaccine/Pf | 131 | $18,440 |
| XareltoRivaroxaban | 17 | $16,786 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 151 | $9,844 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArexvy, Shingrix, Trelegy Ellipta, Twinrix, Havrix | $805 | $2,014,8887,839 claims |
| PfizerAbrysvo, Eliquis | $37 | $151,885421 claims |
| AstraZenecaFarxiga | $637 | $43,59367 claims |
| Boehringer IngelheimJardiance, Tradjenta | $63 | $26,88430 claims |
| Novo NordiskOzempic | $178 | $25,04924 claims |
| Johnson & JohnsonXarelto, Invokana | $57 | $23,05530 claims |
| MerckJanuvia, Gardasil 9 | $43 | $22,73947 claims |
| Lilly USA, LLCMounjaro | $572 | $19,32417 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $255 | $7,16111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lubbock
- Michael MendezLubbock$368K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.